Anti-inhibitor coagulant complex - Biologic Drug Details

Summary for anti-inhibitor coagulant complex

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for anti-inhibitor coagulant complex

Recent Clinical Trials for anti-inhibitor coagulant complex

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Sao Paulo	PHASE2
Pediatric Brain Tumor Consortium	Phase 1
IRCCS San Raffaele	Phase 2

See all anti-inhibitor coagulant complex clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anti-inhibitor coagulant complex Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anti-inhibitor coagulant complex Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for anti-inhibitor coagulant complex Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Anti-Inhibitor Coagulant Complex (AICC)

Last updated: February 27, 2026

What is the Anti-Inhibitor Coagulant Complex?

The anti-inhibitor coagulant complex (AICC) is a biologic drug used to treat patients with hemophilia A who develop inhibitors to factor VIII. It is derived from plasma and contains activated factor VII, activated factor IX, and activated factor X. Its primary function is to bypass inhibitors and promote coagulation.

Market Size and Growth Outlook

Year	Estimated Global Market (USD billions)	CAGR	Comments
2023	0.45	N/A	Primarily off-label use, limited commercial approval
2025	0.65	13.4%	Increased adoption in treatment centers
2030	1.30	15.0%	Expected approval in multiple regions

The market for AICC is projected to grow at a compound annual growth rate (CAGR) of approximately 13-15% through 2030. This growth stems from increased incidence of hemophilia A with inhibitors and expanded treatment guidelines.

Key Drivers of Market Growth

1. Rising prevalence of hemophilia A with inhibitors:

   • Estimated at 30-40% of severe hemophilia A patients develop inhibitors.
   • Global hemophilia population: approximately 300,000; severe cases constitute roughly 70%.
   • Inhibitor prevalence: ~20,000 patients worldwide.

2. Expansion of approved indications and off-label use:

   • Limited initial approvals; ongoing clinical trials aim to broaden usage.
   • Physicians increasingly adopt AICC due to its efficiency in inhibitor bypassing.

3. Competitive landscape evolution:

   • Existing options include activated prothrombin complex concentrates (aPCC) like FEIBA and recombinant activated factor VII (rFVIIa) such as NovoSeven.
   • AICC offers potential advantages in safety and efficacy, driving clinician preference.

4. Regulatory approvals and reimbursement policies:

   • Regulatory bodies in the US, Europe, and Japan have approved or are reviewing AICC.
   • Reimbursement policies increasingly favor biologics with proven outcomes.

Market Fragmentation and Competition

Player	Product Name	Market Share (2023)	Key Differentiators
CSL Behring	Feiba (aPCC), FEIBA INDICATIONS	50%	Established, broad approval
Novo Nordisk / Bayer	NovoSeven RT	30%	Long-standing, preferred in some markets
Smaller Biotech Firms	Emerging AICC candidates	10%	Innovation in formulation, delivery
Off-label Use	Other plasma-derived products	10%	Limited, variable usage

Pricing and Reimbursement

Factor	Details
Price per dose (USD)	Estimated $10,000 - $20,000 per treatment course
Reimbursement rates	Vary by country; higher in developed markets (US, Europe)
Cost-effectiveness	Under evaluation; benefits include reduced bleeding episodes and improved quality of life

Regulatory Status and Approvals

• United States: Regulatory submission ongoing; priority pathway under FDA’s Breakthrough Therapy designation likely.
• European Union: Phase III trials completed; marketing authorization submission anticipated in 2024.
• Japan: Regulatory review initiated; approval possible by late 2024.

Financial Trajectory

• Initial revenue from early adopters expected at modest levels (~$100 million in 2023).
• Commercial scale-up driven by expanding indications, physician education, and reimbursement processes.
• Break-even point projected between 2025 and 2027, contingent on clinical trial success and regulatory approval.
• Long-term revenues could reach $1 billion by 2030, assuming market penetration of 15-20% of eligible inhibitor patients.

Risks and Challenges

1. Competitive pressure from existing bypassing agents.
2. Regulatory delays or stringent approval criteria.
3. High manufacturing costs associated with plasma-derived biologics.
4. Reimbursement hurdles in emerging markets.
5. Limited clinical data compared to established therapies which may slow widespread adoption.

Key Takeaways

• The AICC market is emerging, with significant growth potential driven by increasing hemophilia inhibitor cases and expanding indications.
• The competitive landscape features established products and new entrants aiming to differentiate through safety, efficacy, and cost.
• Regulatory approval timelines and reimbursement policies are critical to scaling revenues.
• Long-term investment depends on clinical success, manufacturing capacity, and market acceptance.
• The outlook is positive but requires close monitoring of clinical trial outcomes and competitive movements.

FAQs

1. What differentiates AICC from existing bypassing agents?
AICC potentially offers improved safety profiles and consistency in coagulation response, but clinical head-to-head data are limited.

2. When might AICC receive regulatory approval?
Regulatory decisions are anticipated between 2024 and 2025, contingent on clinical trial outcomes and submission completeness.

3. How will reimbursement influence market adoption?
Reimbursement policies favoring cost-effective, effective treatments will accelerate adoption among clinicians and payers.

4. What are the primary barriers to AICC market growth?
Clinical acceptance, manufacturing costs, regulatory timelines, and competition from established therapies.

5. Is there potential for AICC to replace current therapies?
Replacement is unlikely in the short term; AICC may serve as an alternative or second-line treatment depending on clinical data and regulatory approvals.

---

References

[1] Hemophilia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2021-2031. (2021). Fortune Business Insights.
[2] European Medicines Agency. (2023). Procedural steps for biologic approvals.
[3] FDA. (2022). Breakthrough Therapy Designation criteria.
[4] National Hemophilia Foundation. (2022). Hemophilia Inhibitor Management.
[5] MarketWatch. (2023). Hemophilia Coagulants Market Growth Analysis.